Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platelet-derived growth factor receptor alpha (PDGFRα), also known as CD140a, is a cell surface receptor tyrosine kinase. It is a critical regulator of cellular growth, differentiation, and development, particularly in mesodermal tissues. PDGFRα plays essential roles during embryogenesis and in maintaining tissue homeostasis. Ligand binding (PDGF-A, -B, -C) induces receptor dimerization and autophosphorylation, activating downstream signaling pathways like PI3K/AKT and MAPK. Mutations in PDGFRA are linked to GISTs and clonal hypereosinophilic syndromes, making it a clinically relevant target for therapies like imatinib.
Tyrosine kinase inhibitor; inhibits the tyrosine kinase activity of PDGFRα, preventing receptor autophosphorylation and downstream signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet-derived growth factor receptor alpha subunit.